Frontline Therapies Archives

April 26, 2023

ASH 2022: Dr. Bill Wierda on Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

The combination of ibrutinib plus venetoclax is an effective first-line treatment for high-risk chronic lymphocytic leukemia (CLL)

April 26, 2023

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

We discuss combination therapies for CLL and SLL, focusing on the combination of ibrutinib plus venetoclax.

April 26, 2023

ASH 2022: Dr. Bill Wierda on Acalabrutinib as a First-line Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Final data from a phase 1/2 clinical trial with six years of follow-up show that first-line acalabrutinib produces high response rates and rapid, durable responses in patients with CLL

March 24, 2023

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

Adding venetoclax to ibrutinib in high-risk patients with chronic lymphocytic leukemia (CLL) who have been on ibrutinib for more than one year was very effective in helping patients reach undetectable measurable residual disease (uMRD).

March 16, 2023

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

The first interim analysis of the Phase 2 HOVON 158/Next Step Trial was conducted halfway through a 15-month course of treatment with ibrutinib and venetoclax. As compared to baseline, PET-CT scanning showed a decrease in metabolic activity in all but one patient. However, despite the decrease in metabolic activity

March 16, 2023

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

Targeted therapies have greatly improved survival outcomes for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). For example, Ibrutinib is so effective at controlling CLL/SLL that the overall survival of patients treated with first-line ibrutinib is no different from that of the general population.

March 16, 2023

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who achieved undetectable measurable (or minimal) residual disease (uMRD) after fixed-duration ibrutinib + venetoclax treatment continue to have excellent outcomes four years after stopping initial therapy. The results of this study suggest that if patients achieve uMRD remission,

February 23, 2023

ASH 2022: Dr. Talha Munir on How IgHV Mutation Status in Chronic Lymphocytic Leukemia (CLL) Affects Response to Taking Ibrutinib in Combination with Venetoclax

In this study, patients with IGHV unmutated chronic lymphocytic leukemia (CLL) responded better to combination ibrutinib + venetoclax than patients with IGHV mutated CLL and were more likely to achieve measurable residual disease (MRD) negativity in the peripheral blood and bone marrow.

February 23, 2023

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

Fixed duration combination therapy of obinutuzumab, ibrutinib, and venetoclax with treatment adjustment based on clinical response and results of measurable residual disease testing shows high efficacy and safety for the front-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with del (17p) or TP53 mutation offering exciting hope

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Frontline Therapies

ASH 2022: Dr. Bill Wierda on Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia

ASH 2022: Dr. Neil Kay on Combination Therapies for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Bill Wierda on Acalabrutinib as a First-line Therapy for Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

ASH 2022: Dr. Philip Thompson on Venetoclax for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) Who Have Been on Ibrutinib More Than a Year

ASH 2022: Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

ASH 2022: Dr. Paolo Ghia on Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) who Received First-Line Treatment with Ibrutinib

ASH 2022: Dr. John Allan on Outcomes for Chronic Lymphocytic Leukemia (CLL) Patients with Undetectable Measurable Residual Disease (MRD) After Treatment with Ibrutinib Plus Venetoclax

ASH 2022: Dr. Talha Munir on How IgHV Mutation Status in Chronic Lymphocytic Leukemia (CLL) Affects Response to Taking Ibrutinib in Combination with Venetoclax

ASH 2022: Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab, Ibrutinib, and Venetoclax in Untreated Patients with CLL with 17p Deletion/TP53 Mutation

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT